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Abstract
Because of its highly bioactive properties sphingosine 1-phosphate (S1P) is an attractive 
target for the treatment of several diseases. Since the expression of sphingosine kinases as 
well as S1P receptors was demonstrated in the kidney, questions about the physiological 
and pathophysiological functions of S1P in this organ have been raised. In this review, we 
summarize the current state of knowledge about S1P-mediated functions in the kidney. A 
special focus is put on S1P modulated signal transduction in renal glomerular and tubular cells 
and consequences for the development and treatment of several kidney diseases, diabetic 
nephropathy, glomerulonephritis, ischemia-reperfusion injury, as well as for Wilms tumor 
progression.
Introduction
The sphingolipid molecule sphingosine 1-phosphate (S1P) was first reported as signaling 
molecule by Ghosh et al. [1] who proposed that sphingosine is intracellularly converted to 
S1P, which in turn triggers an enhanced calcium mobilization from a calcium pool including 
an inositol trisphosphate sensitive pool. In parallel, the group of Sarah Spiegel showed that 
exogenously added sphingosine is able to enhance proliferation of Swiss 3T3 fibroblasts [2] 
which was later specified to be due to the intracellular conversion of sphingosine to S1P 
[3]. Indeed, a sphingosine kinase (SK) activity had already been characterized many years 
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before in blood platelets [4]. To date, two subtypes of SK, SK-1 and SK-2, and several splice 
variants of each subtype, have been cloned and partially characterized (reviewed in [5]). 
These subtypes are ubiquitously expressed but show differential biochemical properties and 
subcellular localizations. Therefore, it is very likely that S1P generated by the two enzymes 
at different subcellular sites may exert different cellular functions. S1P mainly acts as an 
extracellular ligand for specific cell surface receptors, the S1P receptors (S1PRs), which 
belong to the superfamily of G protein-coupled receptors. Five subtypes of these receptors 
have been identified, denoted S1P1-5, which trigger various cell responses depending on the 
cell type, including proliferation, migration and survival. Moreover, several intracellular 
targets for S1P were recently identified, indicating novel modes of action for this lipid 
second messenger [6, 7]. Because of its highly bioactive properties S1P is an attractive 
target for the treatment of several diseases. Since the expression of SKs as well as S1PRs was 
demonstrated in kidney lysates as well as in isolated renal cells [8-13], questions about the 
physiological and pathophysiological functions of S1P in this organ have been raised. Here, 
we summarize the current state of knowledge about S1P-mediated functions in the kidney. 
A special focus is put on S1P modulated signal transduction in renal cells and consequences 
for the development and treatment of several kidney diseases as well as for renal tumor 
progression.
S1P in renal cells 
In the last years, much effort has been undertaken to unravel the cellular functions of 
S1P in renal cells. Most of these studies have focused on cells isolated from renal glomeruli, 
including  glomerular  visceral  epithelial  cells  (podocytes),  mesangial  cells  (MC)  and 
glomerular endothelial cells (Fig. 1), which play important roles in the pathogenesis of several 
renal diseases including diabetic nephropathy (DN) and various forms of glomerulonephritis 
(GN). Other studies have focused on the effect of S1P on tubular cells which are thought to 
be critically involved in the pathogenesis of renal ischemia-reperfusion-induced injury (IRI). 
Glomerular cells 
Glomerular MC are smooth muscle-like cells located in the intercapillary space of the 
glomerulus. Physiologically, they participate in the regulation of the glomerular filtration 
as well as in the preservation of structural integrity of the glomerulus (reviewed in [14-
16]). In addition, in many forms of glomerular diseases MC are activated and show altered 
migration and proliferation, increased production of extracellular matrix (ECM) components 
and inflammatory mediators (reviewed in [15-17]). Chen et al. [18] first demonstrated 
that in cultures of rat MC, S1P as well as sphingosylphosphorylcholine act as exogenous 
stimuli  to  trigger  increased  calcium  mobilization  and  arachidonic  acid  release  through 
phospholipase C activation. Subsequently, Gennero et al. [11] reported that S1P can either 
increase proliferation of MC in culture or induce cell death depending on the cell density of 
the cultures. These authors also characterized for the first time the S1PR expression profile 
in rat mesangial cells which included the S1P1-3, and S1P5 [11]. The proliferative capacity of 
exogenous S1P on MC was confirmed by Hanafusa et al. [19]. These authors also showed that 
S1P is neither formed nor released upon cell stimulation with platelet-derived growth factor 
(PDGF), which is normally secreted from platelets present in damaged or inflamed glomeruli 
[20]. However, other studies clearly revealed a cross-communication between PDGF and 
S1P signaling in MC proliferation. Katsuma et al. [10] showed that PDGF up-regulated S1P2 
expression. Furthermore, they suggested the specific involvement of S1P2 and S1P3 in MC 
proliferation. Both receptor subtypes were shown to couple through a pertussis toxin (PTX)-
sensitive G protein that resulted in the activation of the classical mitogen activated protein 
kinase/extracellular signaling regulated kinase (MAPK/ERK) pathway. A connection between 
PDGF and S1P was also forwarded by Olivera and Spiegel [21] who showed that PDGF can 
activate SK-1 and induce a nuclear translocation of the enzyme [22]. In this context, S1P was 
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postulated as an intracellular second messenger mediating PDGF-induced proliferation of 
mouse fibroblasts [21]. Also, Katsuma et al. [10] showed that PDGF induced SK expression 
and activity as well as intracellular S1P formation in rat MC, leading to the conclusion that 
SK is at least in part involved in PDGF-induced MC proliferation. Altogether, these studies 
clearly established a prominent role of the SK/S1P pathway in MC proliferation. 
In addition to the proliferative effect, S1P is well known to trigger cell survival. In this 
context, Hofmann et al. [13] investigated the role of the two SK isoforms, SK-1 and SK-2, in 
staurosporine induced apoptosis. They showed that renal MCs isolated from SK-2 knockout 
mice  were  resistant  to  staurosporine-induced  apoptosis  whereas  the  absence  of  SK-1 
led to a more pronounced apoptotic response to staurosporine. These data suggested an 
opposite function of SK-1 and SK-2 on apoptotic cell responses and were in line with the 
previous report by Liu et al. [23] who showed that SK-2 is a pro-apoptotic enzyme, which 
through its BH3 domain binds and traps the anti-apoptotic Bcl-2-family member Bcl-XL. 
Additionally, Igarashi et al. [24] demonstrated that SK-2 is a nuclear protein which inhibits 
DNA synthesis in various cell lines. In contrast to the poorly understood functions of SK-2 on 
cell growth and death, the anti-apoptotic function of SK-1 has been more extensively studied 
and various reports confirmed this hypothesis. In this regards, it was recently shown that 
certain nephroprotective drugs such as glucocorticoids [25] or PPARγ agonists [26] act at 
least partially by up-regulating SK-1 expression and activity and consequently increase the 
cellular S1P level in MC which in turn mediates protection from either stress-induced cell 
death [25] or fibrotic reactions [26].
An effect of S1P on cell migration of various cell types is also well established. This 
observation may have impact not only on cancer cell growth, progression and metastasis, 
but also for renal diseases where migration of MCs is a typical feature like in the early phase 
of mesangioproliferative glomerulonephritis. Depending on the S1PR subtype expression 
pattern in different cell types, exogenous S1P can either stimulate (via S1P1 or S1P3) or 
inhibit (via S1P2) migration (reviewed in [27]). In renal MC cultures, it was demonstrated 
that extracellular S1P, but also the extracellular nucleotides ATP and UTP which act through 
P2Y purinoceptors, can stimulate MC migration [12]. Down-regulation of SK-1 by siRNA 
transfection  of  MC,  abrogated  the  migratory  response  induced  by  the  nucleotides  and 
remarkably also by S1P [12] suggesting that SK-1 is a key enzyme mediating migration by 
various extracellular stimuli including S1P itself. This also agrees with the data by Meyer zu 
Heringdorf et al. [28] who showed that activation of S1PRs enhance SK-1 activity in human 
embryonic kidney cells (HEK293). These authors speculated that the cells may respond to 
SK-1 up-regulation/activation by an up- or down-regulation of certain S1PR subtypes. 
Fig. 1. Cellular and structural 
components of a renal glom-
erulus.  The  immunohisto-
chemical staining (right pan-
el) was generated using a kid-
ney  paraffin  section  stained 
with  periodic  acid-Schiff  re-
agent.  Counterstaining  was 
performed using Mayer`s He-
malaun.
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We recently forwarded the concept that extracellular S1P (eS1P) and intracellular S1P 
(iS1P) could have opposite effects on certain cell responses such as a fibrotic response. The 
pro-fibrotic marker connective tissue growth factor (CTGF) is well known to be up-regulated 
and secreted by transforming growth factor β (TGF-β) in vitro and in vivo in the course of 
fibrotic events that are common endpoints of nearly all chronic kidney diseases. The first 
hint that eS1P affected the pro-fibrotic CTGF came from cDNA microarray analyses of S1P 
and dihydro-S1P stimulated MC that showed an up-regulation of CTGF mRNA expression 
by S1P and dihydro-S1P [29]. Later on, Xin et al. [30] demonstrated that also CTGF protein 
expression and secretion is enhanced by eS1P and forwarded a novel crosstalk activated by 
S1P and its receptors and the TGF-β/Smad signaling pathway. Thus, via one of the S1PRs 
S1P cross-activated the TGF-β receptor complex and thereby acted as a TGF-β mimetic in 
renal MC. A similar mechanism of S1P-triggered Smad activation was later also observed 
in  keratinocytes  [31]  and  in  the  murine  Langerhans  cell  line  XS52  [32].  Furthermore, 
the mechanism of CTGF up-regulation by S1P seemed not to be restricted to MC, but also 
occurred in cells of epithelial origin such as in podocytes [33]. In addition, Xin et al. [34] 
demonstrated that FTY720 and phospho-FTY720 were able to induce CTGF expression in 
renal MCs via cross-activation of the Smad signaling cascade. Consistent with previously 
published effects of S1P [30], FTY720 and its derivative phospho-FTY720 induced Smad 
phosphorylation in a PTX insensitive but suramin dependent manner. Suramin was reported 
as a selective S1P3 antagonist when compared to the other S1PR subtypes [35] which made 
it temping to suggest that the S1P3 would be involved in the S1P- and FTY720-triggered 
Smad  cross-activation  and  subsequent  CTGF  expression  [30,    34].  However,  suramin  is 
a rather unspecific drug and many other G protein-coupled receptors were shown to be 
affected by suramin as well. Therefore, it remains unclear whether S1P3 is indeed involved 
in the fibrotic response in renal MC. In this context, Katsuma et al. [36] suggested that S1P2 
and/or S1P3, are involved in the S1P-induced CTGF expression in renal MCs. More recent 
data in tumor cells rather suggested the S1P2 to be involved in the pro-fibrotic effects of eS1P 
[37]. This conclusion is derived from the finding that phospho-FTY720, which cannot bind 
to the S1P2 [38], had no effect on CTGF expression in the Wilms’ tumor cell line WiT49 ([37], 
see below). Furthermore, the S1P2 antagonist JTE-013 completely blocked the S1P-induced 
CTGF expression in these cells, whereas the S1P1 antagonist VPC-44116 did not. 
The  pro-fibrotic  potential  of  eS1P  measured  by  the  up-regulation  of  CTGF  protein 
expression and secretion was also confirmed for human podocytes [33]. These authors also 
investigated the role of SK-1 in the expression of CTGF in human podocytes. Interestingly, 
they could show that the pro-fibrotic cytokine TGF-β strongly up-regulated the protein 
expression  and  activity  of  SK-1.  Strikingly,  this  SK-1  activation  and  generation  of  iS1P 
attenuated CTGF expression in podocytes, thus, iS1P rather acted anti-fibrotic. These results 
were further corroborated by the use of caged S1P which is an inactive S1P derivative that 
is readily taken up by cells and upon photolysis is cleaved into mature S1P [39]. Caged S1P, 
when applied to cells and photolysed to generate iS1P, also attenuated CTGF expression 
[33].  In  addition,  SK-1  overexpression  expected  to  generate  high  amounts  of  iS1P  also 
reduced CTGF expression in the supernatant, whereas a pharmacological inhibitor of SK-1, 
SKI II (2-(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole), led to a more pronounced CTGF 
expression upon TGF-β treatment. These findings in podocytes were recently also confirmed 
for MC [26]. These authors demonstrated that thiazolidinediones (TZDs) which are agonists 
of the peroxisome proliferator-activated receptor gamma, also induce SK-1 expression and 
activity and the generation of iS1P in renal MC, which was functionally coupled to lower 
amounts of CTGF. Pharmacological and genetic approaches to inhibit SK-1 abolished this 
effect in vivo and in vitro, suggesting that the known anti-fibrotic potential of TZDs is at least 
partially due to iS1P generation [26]. All these data strongly suggest that targeting of eS1P is 
a valid approach to prevent fibrotic processes. Alternatively, one may stimulate intracellular 
SK-1 activity and increase the levels of iS1P. However, this is a double edged sword since 
iS1P could as well be secreted by still unclear mechanisms and once in the extracellular 
space it may turn into a pro-fibrotic signal (Fig. 2). 
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Lan et al. [40] reported the up-regulation of SK-1 under high glucose conditions which 
was paralleled by increased iS1P levels and fibronectin expression in MCs. Surprisingly, SK-1 
siRNA and the SK inhibitor N,N-dimethylsphingosine (DMS) abolished the high glucose-
induced fibronectin expression, proposing a rather pro-fibrotic role of SK-1. By the use of 
the S1P2 antagonist JTE-013 the authors further suggested that S1P2 is involved in this pro-
fibrotic response [40], in line with various previous studies highlighting the pro-fibrotic 
contribution of eS1P and S1P2. 
Tubular cells
Among a wide range of tubular cell lines available, the human HK-2 cell line and the 
mouse TKPTS proximal tubular cell line are the most widely used cell culture models for 
current studies to unravel the regulatory function of S1P in IRI based molecular events. The 
proximal tubule is highly oxygenated under healthy conditions and is associated with a high 
metabolic rate [41, 42]. Proximal tubular cells represent the primary site of damage upon 
ischemia/reperfusion and therefore, these cells are considered a suitable model system 
to study in vitro the molecular details of IRI. Immortalized HK-2 cells were derived from 
normal  adult  human  kidney  proximal  tubular  epithelium  by  transduction  with  human 
papilloma virus 16 E6/E7 [43]. Using this HK-2 cell line, Kim et al. [44] demonstrated that 
the anesthetic drug isoflurane induced SK-1 mRNA expression as well as SK-1 activity which 
resulted in increased S1P generation. They also found that in vivo in a murine model of 
IRI, isoflurane protected from renal failure and necrosis and that the protection was lost 
by SK inhibitor treatment and by a S1P1/3 antagonist ([44], see below). The protective and 
anti-necrotic mechanism in HK-2 cells was suggested to include S1P1-mediated ERK and 
protein kinase B/Akt activation and heat shock protein 70 induction [45] as well as release 
of TGF-β1 [46]. They put forward the hypothesis that an interaction between isoflurane and 
plasma membranes and particularly caveolar microdomains would lead to TGF-β1 release, 
which in turn stimulates SK-1 and S1P formation with a subsequent S1P1 activation to ERK 
stimulation  [47].  A  novel  therapeutic  application  for  inhalational  anesthetics  was  thus 
suggested by the authors. A similar protective effect of S1P1 activation was also reported 
for the mouse TKPTS cell line [48]. Additionally, overexpression of SK-1 in HK-2 cells also 
protected against peroxide-induced necrosis and led to enhanced heat shock protein 27 
expression that was reversed by S1P1 antagonism [49]. Finally, Park et al. [50] showed 
Fig. 2. Schematic overview on the opposite effects of intracellular (left panel) and extracellular (right panel) 
S1P for the expression of pro-fibrotic CTGF in renal glomerular cells. Abbreviations used: CTGF, connective 
tissue growth factor; S1P, sphingosine-1-phosphate; S1PR, S1P receptor; SK-1, sphingosine kinase 1; Sph, 
sphingosine; TGF-β, transforming growth factor β; TGF-βR, TGF-β receptor.
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that the selective S1P2 antagonist JTE-013 induced SK-1 expression and further attenuated 
necrosis and apoptosis in HK-2 cells, whereas a S1P2 agonist had the opposite effect. Indeed, 
the finding that a receptor antagonist in the absence of the receptor ligand has gene inducing 
capability is surprising at a first glance and it can presently not be excluded that JTE-013 
may have additional cellular effects, e.g. acting as a partial agonist or even unspecifically.
Altogether, these in vitro data further established the protective function of S1P in an 
increasing number of cellular systems.
S1P in renal disease models 
First evidence for the importance of S1P in renal physiology was given by Bischoff 
et al. [51-53] who showed that intravenous and intrarenal infusions of S1P led to renal 
vasoconstriction and caused natriuresis in spite of a reduction of renal blood flow ([51-
53], reviewed in [54]). The effects were blocked by PTX indicating the involvement of at 
least one Gi-coupled S1PR [52]. More than one decade later, Zhu et al. [55] readdressed the 
involvement of S1PR subtypes in renal function. They demonstrated that intramedullary 
administration of FTY720 produced an increase in sodium excretion, an effect which was 
blocked  with  the  S1P1  antagonist  W146.  Consequently,  the  authors  suggested  that  S1P 
might produce natriuretic effects via activation of S1P1, which in turn affects transport 
mechanisms in the renal medulla [55]. The understanding of S1P signaling in many cellular 
systems promotes the idea to use this knowledge to treat diverse diseases. To date, various 
strategies are discussed to either specifically activate or inhibit S1PRs or to deplete S1P from 
the serum/plasma and thereby to diminish its pathophysiological actions. The usefulness of 
eliminating plasma S1P levels in the treatment of angiogenic diseases was recently proven 
by using a neutralizing anti-S1P antibody (sonepcizumab®). Humanized S1P antibodies were 
effective in blocking S1P-mediated release of pro-angiogenic and prometastatic cytokines in 
cancer models [56, 57] and also reduced injury in a laser-induced retinopathy model [58]. A 
different approach was recently forwarded by Huwiler et al. [59] who used recombinant S1P 
lyase from a thermostable bacterium (Symbiobacterium thermophilum). This prokaryotic 
enzyme,  in  contrast  to  the  eukaryotic  enzyme,  lacks  a  transmembrane  sequence  at  its 
N-terminus and therefore lacks membrane association. Intravenous application of this S1P 
lyase rapidly degraded plasma S1P levels but the effect was only transient and after 6h, plasma 
S1P had recovered to normal levels again [59]. When used in a neovascularization model of 
the developing chicken embryo, the chorioallantoic membrane (CAM) model, recombinant 
Symbiobacterium thermophilum S1P lyase significantly reduced vessel formation triggered 
by injected tumor cells [59].
Numerous studies not only addressed the function of S1P in renal cells but also in 
diverse in vivo diseases models. In the following part, we will recapitulate the present data 
generated in situations of DN, GN and IRI. 
Diabetic nephropathy
Nearly 30% of all diabetic patients develop DN, the major cause of end-stage renal 
failure, which is characterized by clinical symptoms like albuminuria and declined glomerular 
filtration rate. Pathological hallmarks of DN are enhanced secretion and deposition of ECM 
proteins, the expansion of the mesangium and the thickening of the glomerular basement 
membrane (reviewed in [60]). The enhanced secretion of cytokines and growth factors (e.g. 
TGF-β, CTGF) and subsequent MC proliferation and ECM accumulation lead to substantial 
fibrotic changes in the kidney and to the initiation of glomerulosclerosis. 
Based  on  the  in vitro  findings  described  above,  several  groups  investigated  how 
sphingolipid metabolism is altered under diabetic conditions in vivo. A variety of diabetic 
mouse  models  are  available  which  however  show  substantial  differences  in  the  renal 
consequences  of  diabetes  (reviewed  in  [61]).  The  application  of  a  single  high  dose  of 
streptozotocin (STZ) is a widely used and well-established murine model for DN. Its diabetes 
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inducing effect is based on the toxicity of STZ on pancreatic β-cells and it thereby mimics 
specifically type 1 diabetes. Using this STZ model in rats, Geoffroy et al. [62] showed that 
neutral ceramidase and SK activities were significantly up-regulated in isolated glomeruli 
from 4 days STZ treated rats. They also determined increased S1P levels in the glomeruli 
although the sphingosine levels were not altered. Derived from these observations, they 
suggested a possible involvement of sphingolipid metabolites in the glomerular proliferative 
response in the early stage of DN [62]. In line with this notion, Lan et al. [63] showed that 
substances that ameliorated alloxan-induced DN in mice such as berberine, also down-
regulated SK-1 mRNA and protein expression and S1P levels in vivo. Although they did 
not show a causal link between the SK-1 down-regulation and disease amelioration, they 
proposed that inhibition of SK1/S1P may be a new therapeutic option for renoprotection in 
diabetes. The same group recently published that the up-regulation of SK-1 in STZ induced 
DN in mice was paralleled by enhanced levels of the matrix constituent fibronectin [40]. 
Further mechanistic studies however were only performed in MC cultures where the authors 
showed that SK-1 down-regulation or inhibition, or alternative stimulation with exogenous 
S1P,  resulted  in  reduced  fibronectin  production.  In  another  study,  Ren  et  al.  [33]  also 
demonstrated the up-regulation of SK-1 in STZ-induced DN, but these authors by contrast 
suggested the up-regulation of SK-1 to be a protective mechanism in the fibrotic process. 
When using SK-1 knockout mice, they found a more severe STZ-induced disease as measured 
by higher albuminuria and enhanced CTGF expression in kidney sections when compared to 
wild type C57BL/6 mice [33]. The mechanism was further investigated in cultures of human 
podocytes where they could show that TGF-β is not only a strong inducer of fibrogenic CTGF, 
but remarkably also of SK-1. Inhibiting SK-1 by an inhibitor, SKI II, or down-regulating SK-1 by 
siRNA, led to an amplified CTGF expression, whereas overexpression of SK-1 or using caged-
S1P to increase iS1P resulted in reduced CTGF expression. Collectively, these data strongly 
suggested that the TGF-β dependent induction of SK-1 acts like a break in the fibrotic process 
by impeding CTGF expression [33]. Most critical seemed to be the site of action of S1P, either 
intracellularly to promote an anti-fibrotic effect, or extracellularly to trigger a pro-fibrotic 
response [30, 33] (Fig. 2). 
However, the S1PR subtype involved in this pro-fibrotic eS1P action is still unclear. 
By using receptor antagonists both, the S1P2 and S1P3 have been forwarded as candidates 
([30, 40], see above). In a recent study, Imasawa et al. [64] reported an unbalanced mRNA 
expression profile of S1P2 versus S1P1 in diabetic glomeruli in that the ratio of S1P2/S1P1 
was increased in renal glomeruli of rats one year after STZ injection. Considering the in 
vitro findings of Lan et al. [40], i.e. that S1P-stimulated fibronectin expression involves 
S1P2 in MC cultures, the up-regulated mRNA expression of S1P2 in diabetic glomeruli may 
well point to a contribution of this receptor subtype in the pathogenesis of DN. Beside this 
possible disease-promoting effect of S1P2, a protective effect of chronic S1P1 activation has 
been suggested. Thus, Awad et al. [65] showed that STZ-induced DN in rats was reduced by 
either the unselective S1PR agonist FTY720 or the selective S1P1 agonist SEW2871. Since 
SEW2871 in contrast to FTY720, did not reduce circulating lymphocytes, they suggested 
that the renoprotective effect occurred independent of lymphocytes. Also, the protective 
effect of FTY720 was still observed in S1P3 knockout mice excluding this receptor subtype 
in the renoprotective mechanism [65]. Overall, these studies indicated that at least the so far 
discussed receptors, S1P1 and S1P2, might be attractive targets to be further considered in 
the treatment of DN.
Glomerulonephritis
GN is a huge group of diverse inflammatory kidney disease that irrespective of their 
initial  triggering  cause  may  end  in  end-stage  renal  failure.  GN  is  divided  into  several 
subclasses depending on the clinical disease context, the progression, acute or chronic, 
and the histological and immunological changes involved (reviewed in [66]). A hallmark 
of  many  forms  of  GN  is  the  activation  of  MC  leading  to  increased  MC  proliferation, 
inflammatory mediator synthesis and ECM production. Because of their prominent role 
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in the pathogenesis of GN, cultured MCs have become an attractive model system to study 
the molecular mechanisms in GN. The impact of S1P on these events in vitro has been 
discussed above. However, to date no study addressed the role of S1P in the pathogenesis 
of GN in vivo. A few studies investigated the effect of the immune modulator FTY720 on 
the progression of experimental anti-Thy1.1-induced GN. In both acute and chronic anti-
Thy1.1-induced GN in rats, FTY720 was shown to have a beneficial effect [67, 68]. It not 
only reduced lymphocyte infiltration but also reduced proteinuria, tubulointerstitial matrix 
expansion, TGF-β1 and fibronectin expression. These authors suggested that the elimination 
of lymphocytes from the circulation and consequently also from the kidney, is the critical 
protective event triggered by FTY720. However, to date, it is controversially discussed how 
important lymphocytes are in the pathogenesis of the different forms of GN. Along this line, 
Lebleu et al. [69] showed evidence that lymphocytes are dispensable for GN but required for 
interstitial fibrosis. Moreover, Sui et al. [70] recently published that FTY720 acts protective 
in the model of anti-glomerular basement membrane-induced GN in mice, which could 
be mediated by FTY720-dependent down-regulation of S1P1, S1P2 and S1P5 in the spleen 
although the exact mechanisms remained unclear. Taken together, these studies indicate 
that FTY720 might be an attractive approach for the treatment of both acute and chronic GN. 
Moreover, Wenderfer et al. [71] showed that KRP-203, a specific agonist for S1P1 and S1P4 
[72], decreased kidney injury and improved survival in a model of lupus nephritis (MRL/lpr 
mice). Those mice spontaneously develop a systemic autoimmune disease, characterized by 
lymphocyte accumulation in the kidney, which in turn leads to a mesangioproliferative GN 
and glomerulosclerosis (reviewed in [73]). Administration of KRP-203 reduced the number 
of  infiltrating  T-cells  and  circulating  lymphocytes  and  therefore  attenuates  renal  injury 
[71]. Again, this study stresses the idea that activation of S1P1 has beneficial effects in lupus 
nephritis and maybe also other chronic cell-mediated autoimmune diseases.
Ischemia-reperfusion injury
RI is an inescapable event in kidney transplantation often leading to acute kidney 
injury (AKI), which is directly linked to prolonged hospitalization, and increased morbidity 
and mortality (reviewed in [74]). Overall, AKI is associated with a wide range of changes 
in mechanisms such as intense immune responses, coagulation, generation of oxidative 
stress  and  hypoxia,  and  apoptosis.  Since  many  cell  culture  studies  have  suggested  the 
involvement of sphingolipids in these cell responses, a contribution of these lipids also in 
the pathogenesis of IRI seems obvious. The catabolic and metabolic routes of these lipids 
as well as their signaling pathways are considered attractive targets to interfere with IRI 
and progression to AKI. The first evidence that sphingolipids play a role in post-ischemic 
acute renal injury was presented by Zager et al. [75] who showed that in mice subjected to 
renal ischemia, a drop in cortical sphingosine and ceramide levels occurred which either 
normalized again after reperfusion as seen for sphingosine or even rose to supranormal 
levels as detected for ceramide [76, 77]. Paradoxically, acid and neutral sphingomyelinase 
activities both decreased in an unremitting fashion during the ischemia/24 h-reperfusion 
period [77] stressing the hypothesis that ceramide not only derives from sphingomyelin but 
also from the de-novo synthesis pathway. Recently, Jo et al. [78] used SK-1 and SK-2 deficient 
mice to investigate whether the conversion of ceramide/sphingosine to S1P has an effect 
on renal ischemia/reperfusion injury. Theoretically, depletion of SK-1 or SK-2 should lead 
to increased sphingosine and eventually also ceramide levels. They found no effect of SK-1 
depletion on the extent of injury, but they observed more severe injury in SK-2 deficient mice 
[78] leading the authors to conclude that SK-2 is a protective enzyme. Opposite to this, Park 
et al. [49] found enhanced IRI in SK-1 deficient mice, but reduced IRI in SK-2 deficient mice. 
Moreover, Kim et al. [44] used the volatile anesthetic isoflurane to activate SK-1 and generate 
S1P that, in turn, via activation of S1P1 protected mice from renal failure in a murine model 
of IRI. In SK-1 deficient mice, no protection by isoflurane occurred any more [44]. Also, 
the two SK-1 inhibitors DMS and SKI II abrogated the nephroprotective effect of isoflurane 
[44, 49]. The reason for the discrepancy between the results of Jo et al. [78] and Park et al. 
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[49] remained unclear but could be due to differences in the experimental setup, e.g. both 
groups used a different model of AKI as well as mice from different sources. However, SK 
deficient mice were also used in a myocardial ischemia/reperfusion injury model. In this 
model, it was shown that both SK-1 and SK-2 deficient mice exerted a more severe myocardial 
injury upon ischemia/reperfusion treatment when compared to wild-type mice [79, 80]. 
Altogether, these studies cannot give a conclusive answer about the functions of SK-1 and 
SK-2 in ischemia/reperfusion injuries, and clearly more studies are needed to clarify the 
contribution of these enzymes in ischemic injury models. More consistent are data about 
an IRI protective function of the product S1P. This hypothesis was further strengthened 
by various studies using the immunomodulatory agent FTY720. Thus, Troncoso et al. [81] 
demonstrated that FTY720 prevented ischemic reperfusion damage in a rat kidney model. 
Since FTY720 in its active phosphorylated form is an unselective S1PR agonist, acting on 
S1P1 and S1P3-5, the question came up which receptor subtype would mediate this protective 
effect of FTY720. Awad et al. [82] showed that the protective effect of FTY720 is due to a 
selective S1P1 activation since the S1P1 antagonist VPC-44116 reversed the protective effect 
of FTY720 on mouse IRI. In addition, the S1P1 selective agonist SEW2871 exerted a similar 
protective effect as FTY720 on IRI [82, 83]. Whether the nephroprotective effect of FTY720 
is only due to the depletion of peripheral lymphocytes or due to a direct effect on kidney 
cells is still a matter of debate. On the one side, Awad et al. [82] suggested that FTY720 
acted via lymphocyte depletion. Moreover, Lai et al. [84] reported that SEW2871 prevented 
T cell infiltration, which also has been implicated in the pathogenesis of IRI [85] by inhibiting 
T cell egress from lymphoid tissue in an early stage. In contrast to these studies, Bajwa et 
al. [48] showed a lymphocyte independent nephroprotective effect of FTY720. Treatment 
with either FTY720 or SEW2871 reduced injury in both Rag-1 knockout mice, deficient 
for T and B lymphocytes, as well as in wild-type mice [48]. These results fit very well with 
their previous observation that the S1P1 antagonist VPC-44116 reversed FTY720-mediated 
nephroprotection [82]. As described above, this lymphocyte-independent protective effect 
was supported by in vitro findings that S1P1 agonists reduce cell death of mouse kidney 
proximal tubule epithelial cells induced by LPS- or H/R through the involvement of the ERK 
and Akt pathways ([48], see above). In addition, Lee et al. [86] also showed a protective 
effect of the S1P and S1P1 pathway in hepatic IRI-induced AKI by preventing endothelial 
cell injury in mice, which was proposed to occur independent of lymphocyte homing [86]. 
Opposite to these studies that support the involvement of S1P1, Jo et al. [78] showed that both 
kidney function and the reduced vascular permeability in IRI were preserved in S1P3
-/- mice 
suggesting the involvement of this receptor subtype in IRI and consequently a protective 
effect of S1P3 antagonism. Regarding the source of S1P that can contribute to the protective 
effect in IRI, Sola et al. [87] proposed that especially macrophages, that undergo apoptosis 
due to IRI, release S1P which, in turn, acts in an autocrine manner on macrophage S1P3 to 
release  neutrophil  gelatinase-associated  lipocalin  (NGAL/Lcn-2)  and  triggers  increased 
proliferation of tubular epithelial cells and thereby prevents from IRI-induced cell death 
[87]. Besides this protective effect of macrophage S1P3, the authors also showed that the 
S1P1 mediates a renal protection against IRI that is independent of macrophages which is in 
line with several previous studies [48, 82]. Furthermore, it was shown that the S1P2 agonist 
SID46371153 exacerbated renal IRI, whereas the S1P2 antagonist JTE-013 protected against 
renal IRI [50]. In terms of mechanism, these authors showed that inhibition of S1P2 led to 
Rho kinase and HIF-1a activation, SK-1 up-regulation, S1P generation and activation of   
S1P1  that  consequently  triggered  renoprotection.  However,  caution  is  required  when   
making conclusions solely based on pharmacological inhibitors such as W146 and JTE-013 
since the selectivity pattern of these compounds is limited and unspecific effects cannot be 
excluded.
S1P and Wilms tumor progression
Wilms tumor or nephroblastoma is an embryonic cancer of the developing kidney 
that  is  considered  to  derive  from  renal  stem  or  progenitor  cells  that  show  a  failure  in 
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differentiation. Wilms tumor is the most prevalent renal malignant tumor in children. But 
fortunately, it is also one of the most treatment-responsive tumors (reviewed in [88]). Thus, 
several therapeutic options are available to treat Wilms tumor successfully. Since plenty 
of evidence exists that supports a key role for S1P in tumor growth and progression both 
in vitro and in vivo (reviewed in [89]), it is tempting to speculate that S1P may also play a 
crucial role in Wilms tumor pathogenesis. By microarray analysis of advanced Wilms tumor 
tissue, Zirn et al. [90] identified a series of differentially expressed genes that could play 
a role in disease progression. Among these genes, CTGF was found to be down-regulated 
in advanced Wilms tumors. Furthermore, the treatment of Wilms tumor cell lines with all-
trans retinoic acid, a potential therapeutic that inhibits cell proliferation and induces cell 
differentiation [91], normalized CTGF expression again [92]. These data led the authors 
to suggest a negative regulatory role for CTGF in Wilms tumor progression. However, the 
generality of CTGF being a negative regulator of tumor development is not given. In this 
view, CTGF has also been described as tumor promoter in various cancers including acute 
lymphoblastic leukemia, breast, cervical, hepatocellular and pancreas cancers, but as tumor 
suppressor in chondrosarcoma, lung and colorectal cancers (reviewed in [93]).
Li  et  al.  [94]  showed  that  in  the  Wilms  tumor  cell  line  WiT49,  S1P  up-regulated 
CTGF  expression  and  subsequently  inhibited  cell  proliferation  which  further  confirmed 
the negative regulatory role of CTGF on Wilms tumor growth. The S1P-triggered effect 
on CTGF was mediated by the S1P2 [94]. In addition, the overexpression of S1P2 reduced 
the S1P-stimulated migration of Wilms tumor cells [95] consistent with other studies on 
various other cancer cell lines that also showed a negative role of S1P2 in cell migration 
(reviewed in [27]). However, it should be kept in mind that S1P2 may also signal to other 
genes. In this context, Li et al. [96] demonstrated that in WiT49 cells, the S1P/S1P2 axis can 
also induce cyclooxygenase-2 (COX-2) expression and leads to enhanced prostaglandin E2 
(PGE2) formation. However, PGE2 is known to mediate growth and progression of various 
tumor types by promoting angiogenesis and inhibiting apoptosis (reviewed in [97]) and 
it was shown that COX-2 inhibition significantly suppressed tumor growth even in vivo in 
an orthotopic xenograft model of human Wilms tumors in mice [98]. Thus, whether S1P2 
activation or inhibition is more favorable in treating Wilms tumors remains uncertain.
Conclusions and future perspectives
The discovery that S1P can act in a dual way either from the extracellular space as 
ligand to cell surface S1PRs, or as a second messenger in the intracellular compartments 
to regulate a multitude of cellular processes including cell proliferation, survival, migration 
and modulation of gene transcription sometimes in an opposing manner, has triggered a 
huge research effort to understand the molecular mechanisms of S1P action and to develop 
strategies to regulate intracellular and extracellular S1P levels. The availability of suitable 
tools  like  genetically  modified  mice,  low  molecular  mass  inhibitors  and  highly  potent 
receptor agonists and antagonists with improved properties will be helpful in clarifying these 
processes. In the past, the development of selective S1PR subtype agonists and antagonists 
seemed to be most attractive. Indeed, first data display a renoprotective effect of S1PR 
agonists, e.g. SEW2871 (S1P1) and KRP-203 (S1P1,4), and antagonists, JTE-013 (S1P2), in 
various animal models of renal diseases such as diabetic nephropathy and glomerulonephritis 
(Fig. 3). In this context, especially the development and market introduction of FTY720 
(fingolimod, Gilenya®) for the treatment of multiple sclerosis has undoubtedly proven the 
therapeutic relevance of targeting S1PRs and has strongly boosted research on sphingolipids 
in various other inflammatory and proliferative diseases including kidney diseases. Beside 
S1PR-specific strategies, the effectiveness of S1P trapping in serum/plasma by a neutralizing 
anti-S1P antibody (e.g. sonepcizumab®) or S1P degradation by the use of recombinant S1P 
lyase to diminish its pathophysiological actions needs to be evaluated. In addition, several 
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studies reveal that targeting SK-1 seems to be a worthwhile strategy to treat renal diseases 
(Fig. 3). However, some controversial data about the beneficial effect of either activation of 
SK-1 and subsequent formation of iS1P or its inhibition by SKI-II or DMS make clear that, 
regarding kidney diseases, the picture of S1P and its involvement in the pathogenesis of 
such diseases is still controversial. Therefore, the usefulness of targeting the SK/S1P/S1PR 
signaling device in kidney diseases awaits further clarification in future studies.
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